<DOC>
	<DOCNO>NCT02637310</DOCNO>
	<brief_summary>A multi center , randomize , double-blind , placebo-controlled , parallel , phase 2b clinical trial evaluate efficacy safety N02RS1 patient acute bronchitis</brief_summary>
	<brief_title>Evaluate Efficacy Safety N02RS1 Patient With Acute Bronchitis</brief_title>
	<detailed_description>Suitable subject randomize experimental control group . The subject eat IP 7days . Visit 3 ( 3 day ) evaluate BSS phone call visit 4 ( 8 day ) evaluate efficacy safety .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Patients 19 , 75 age Patients acute bronchitis , sputum symptom , BSS 7 point . Patients acute bronchitis within 7days . Nonpregnant , patient agree contraception . Patients write diary available communicate . Patients voluntarily agree Patients hypersensitivity drug . Patients gotten systemic steroid treatment within 4 week . Patients gotten treatment antibiotic , bronchodilator , painkiller secretagog within 7 day . Patients gotten treatment mucus solvent antitussives within 3 day . Patients serious respiratory infection require antibiotic treatment , allergic bronchial asthma , bronchiectasis chronic obstructive pulmonary disease . Patients heart disease , severe kidney , liver disease . The bleeding tendency immunosuppressed patient . Patients clinically significant abnormal value . Pregnant woman nurse mother . Patients alcoholics drug abuse . Patients take clinical trail 's medicine within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>